Holen Sie sich die Stockscreener-App
202.83
0.32%
-0.66
Handel nachbörslich:
202.83
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$203.49
Offen:
$204.75
24-Stunden-Volumen:
1.55M
Relative Volume:
0.36
Marktkapitalisierung:
$314.56B
Einnahmen:
$58.80B
Nettoeinkommen (Verlust:
$10.24B
KGV:
61.86
EPS:
3.2788
Netto-Cashflow:
$8.98B
1W Leistung:
+4.62%
1M Leistung:
+4.43%
6M Leistung:
+137.26%
1J Leistung:
+196.28%
1-Tages-Spanne:
$202.73
$204.75
1-Wochen-Bereich:
$193.55
$204.75
52-Wochen-Spanne:
$61.24
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
202.83 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
927.06 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.97 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
206.69 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
120.85 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
AstraZeneca stock gains 1.77% as strong oncology-driven revenue and earnings growth boosts sentiment - Traders Union
Perpetual Ltd Has $515,000 Stock Holdings in Astrazeneca Plc $AZN - marketbeat.com
Astrazeneca Plc $AZN Stock Holdings Lowered by Cidel Asset Management Inc. - marketbeat.com
AstraZeneca reports positive EMERALD-3 results for HCC - Clinical Trials Arena
AstraZeneca PLC (AZN) Stock Price, News, Quote & History - Yahoo! Finance Canada
AstraZeneca PLC (AZN.L) Stock Price, News, Quote & History - Yahoo! Finance Canada
AstraZeneca PLC (AZN.L) stock price, news, quote and history - Yahoo Finance UK
AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And Returns - Seeking Alpha
Aberdeen Group plc Grows Stake in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca (NYSE:AZN) Cut to Hold at Wall Street Zen - MarketBeat
FTSE AstraZeneca PLC Index (SSAZNS.FGI) Forum & Discussion - Yahoo! Finance Canada
AstraZeneca stock gains 1.77% as bullish technicals and positive trial results fuel buying - Traders Union
AstraZeneca PLC stock: Positive liver cancer trial results spark investor interest - AD HOC NEWS
AZN Stock Quote Price and Forecast - CNN
AstraZeneca (AZN) Faces New Tariff Challenges Amid U.S. Import D - GuruFocus
AstraZeneca’s New Cancer Combo Trial Signals Steady Progress in Antibody Drug Conjugates - TipRanks
AstraZeneca climbs Thursday, outperforms market - MarketWatch
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,500 GBp From 16,000 GBp - Insider Monkey
AstraZeneca reports positive phase III results for Imfinzi and Imjudo in liver cancer - Investing.com
AstraZeneca (NYSE: AZN) liver cancer combo boosts PFS in Phase III - Stock Titan
AstraZeneca PLCImfinzi+Imjudo improves PFS in early liver cancer - Research Tree
AstraZeneca’s Liver Cancer Treatment Shows Promise in Phase III Trial - AskTraders
AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial - Reuters
AstraZeneca (AZN) Sees Success in EMERALD-3 Trial for Liver Canc - GuruFocus
ASTRAZENECA : Buy rating from JP Morgan - MarketScreener
Pictet North America Advisors SA Has $8.54 Million Stock Holdings in Astrazeneca Plc $AZN - marketbeat.com
Astrazeneca plc Announces Positive High-Level Results from the Emerald-3 Phase III Trial - marketscreener.com
AstraZeneca hails encouraging data for liver cancer drug regimen - London South East
AstraZeneca upbeat on results of liver cancer treatment trial - sharecast.com
AstraZeneca Says Liver Cancer Drug Combination Extends Progression-Free Survival in Phase 3 Trial - marketscreener.com
AstraZeneca Reports Positive Phase III EMERALD-3 Results In Unresectable Liver Cancer - DirectorsTalk Interviews
Deutsche Bank Maintains Sell on AstraZeneca (AZN) - Insider Monkey
Nordic Stocks in North AmericaAstraZeneca Gains 1.8 Percent - MarketScreener
Cowen Maintains Buy on AstraZeneca PLC (AZN) March 18, 2026 - Meyka
AstraZeneca PLC Stock: Institutional Confidence Builds as Voting Rights Update Signals Stability for - AD HOC NEWS
AstraZeneca PLC Stock Gains Momentum on Positive Tozorakimab Phase 3 Data for COPD Treatment - AD HOC NEWS
Strong clinical milestones drive AstraZeneca stock higher despite mixed momentum readings - Traders Union
AstraZeneca updates total voting rights following admission of new shares - Investing.com
AstraZeneca (NYSE: AZN) updates voting rights and admits new shares - Stock Titan
AstraZeneca PLC Stock (AZN) Moved Up by 3.43% on Apr 1: Facts Behind the Movement - TradingKey
US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial results - Proactive financial news
AstraZeneca reports positive data from Phase III trial of efzimfotase alfa - Clinical Trials Arena
Moody Lynn & Lieberson LLC Increases Holdings in Astrazeneca Plc $AZN - marketbeat.com
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
What's Going On With AstraZeneca Stock Tuesday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca PLC Stock (AZN) Opened Up by 3.38% on Mar 31: Drivers Behind the Movement - TradingKey
AstraZeneca’s ALXN1850 On Blockbuster Trajectory Despite Mixed Phase III Results - Citeline News & Insights
Astrazeneca reports positive phase III results for efzimfotase alfa in hypophosphatasia - Investing.com
ASTRAZENECA : Buy rating from Barclays - MarketScreener
AstraZeneca (AZN) Reports Positive Results from HPP Clinical Tri - GuruFocus
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.02%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):